Faculty introduction, disclosures

Introduction content: cursory refresher and review of AD Epidemiology: Statistics by severity Healthcare burden Pathophysiology with emphasis on present and investigational therapeutic targets Diagnostic challenges, including overlapping dermatologic conditions and differences in patient vs. HCP ratings of severity

Treatment of AD · Goals of care Pharmacotherapy, clinical trial findings, and guideline-recommended care aimed at reducing disease burden: What works and what doesn’t Mild & moderate disease: proactive versus reactive treatment; topical glucocorticoids and calcineurin, PDE-4, and JAK inhibition Severe or persistent disease: Systemic therapies targeting IL-4, IL-13, & JAK; role of oral glucocorticoids and non-targeted immunosuppressants Emerging and future therapies Additional agents targeting IL-13, PDE-4, or JAK IL-31 inhibition Sphingosine 1 phosphate receptor modulation Aryl hydrocarbon receptor modulation Pediatric, adolescent, and adult populations Questions, controversies, considerations, and challenges Refractory cases Duration of systemic therapy Special populations Atopic comorbidities (e.g., eosinophilic esophagitis, asthma, nasal polyps, complex atopic eye disease) Pregnant or lactating women History of severe herpes virus infections or malignancy Individuals undergoing vaccination Pandemic considerations Managing the transitions childhood, adolescence, and adulthood Roles of referral and interdisciplinary care Optimizing a patient’s adherence to therapy Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Summarize the healthcare burden unique to patients with AD and challenges to optimal management.
• Recall the impact of present and emerging pharmacotherapies for AD and the role of different treatment strategies by severity, age, and other patient characteristics.
• Formulate a treatment plan for a patient with AD.

ACCME Activity #202336694

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Jonathan Tam, MD, FAAAAI, FACAAI, Associate Professor of Pediatrics, Keck School of Medicine, University of Southern California, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Incyte.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version